Bruker Corp
NASDAQ:BRKR
Intrinsic Value
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microsc... [ Read More ]
The intrinsic value of one BRKR stock under the Base Case scenario is 82.13 USD. Compared to the current market price of 93.86 USD, Bruker Corp is Overvalued by 12%.
Valuation Backtest
Bruker Corp
Run backtest to discover the historical profit from buying and selling BRKR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bruker's Strong 2023 Performance and FY24 Outlook
2023-Q4 Earnings Call
In 2023, Bruker demonstrated robust financial strength, achieving a third consecutive year of double-digit organic revenue growth, with a 15.9% increase in Q4 and 14.5% for the full year, leading to overall revenue growth of 17.1% to $2.96 billion. Even with strategic investments and acquisitions, non-GAAP EPS grew solidly by 10.3%. The Bruker Cellular Analysis segment, recently restructured, is expected to lessen its EPS dilution from $0.10 to $0.02-$0.03 quarterly, moving towards profitability in FY26. For FY24, Bruker forecasts a promising 5-7% growth in both organic revenue and non-GAAP EPS.
Balance Sheet Decomposition
Bruker Corp
Current Assets | 2.2B |
Cash & Short-Term Investments | 488.3m |
Receivables | 492m |
Other Current Assets | 1.2B |
Non-Current Assets | 2.1B |
PP&E | 691.4m |
Intangibles | 913.1m |
Other Non-Current Assets | 481.2m |
Current Liabilities | 1.2B |
Accounts Payable | 202.7m |
Other Current Liabilities | 999.4m |
Non-Current Liabilities | 1.7B |
Long-Term Debt | 1.2B |
Other Non-Current Liabilities | 510.3m |
Earnings Waterfall
Bruker Corp
Revenue
|
3B
USD
|
Cost of Revenue
|
-1.4B
USD
|
Gross Profit
|
1.5B
USD
|
Operating Expenses
|
-1B
USD
|
Operating Income
|
486.7m
USD
|
Other Expenses
|
-59.5m
USD
|
Net Income
|
427.2m
USD
|
Free Cash Flow Analysis
Bruker Corp
What is Free Cash Flow?
BRKR Profitability Score
Profitability Due Diligence
Bruker Corp's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Bruker Corp's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
BRKR Solvency Score
Solvency Due Diligence
Bruker Corp's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Bruker Corp's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BRKR Price Targets Summary
Bruker Corp
According to Wall Street analysts, the average 1-year price target for BRKR is 86.8 USD with a low forecast of 66.66 USD and a high forecast of 107.1 USD.
Ownership
BRKR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BRKR Price
Bruker Corp
Average Annual Return | 19.08% |
Standard Deviation of Annual Returns | 29.89% |
Max Drawdown | -41% |
Market Capitalization | 13.6B USD |
Shares Outstanding | 137 671 008 |
Percentage of Shares Shorted | 5.45% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. The company is headquartered in Billerica, Massachusetts and currently employs 7,765 full-time employees. The company went IPO on 2000-08-04. The firm operates through four segments: Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Group and Bruker Energy & Supercon Technologies (BEST). The Bruker BioSpin Group segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. The Bruker CALID Group segment designs, manufactures, and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions. The BSI NANO Group segment designs and manufactures advanced X-ray instruments; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; and defect-detection equipment. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices.
Contact
IPO
Employees
Officers
The intrinsic value of one BRKR stock under the Base Case scenario is 82.13 USD.
Compared to the current market price of 93.86 USD, Bruker Corp is Overvalued by 12%.